http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105396141-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2015-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105396141-B |
| titleOfInvention | IRGD- anticancer drug conjugates and its preparation method and application |
| abstract | The invention discloses a kind of iRGD antitumor medicine conjugates and its preparation method and application, which be formed by connecting by chemical bond and iRGD by antitumor drug, structural formula such as formula (I)；Wherein, X 1 For camptothecin and taxanes antitumor drug precursor；L is connecting bridge.The iRGD antitumor medicine conjugates of the present invention have preferable dissolubility in water, directly can be injected intravenously or be processed into other dosage forms；The iRGD antitumor medicine conjugates of the present invention have the ability for inhibiting tumor cell migration and invasion, and can preferably inhibit the growth of tumour cell, and new scheme is provided for oncotherapy research. |
| priorityDate | 2015-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.